BioGaia AB (0GTN) AI Stock Analysis

2 Followers

BioGaia AB

(LSE:0GTN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

High profitabilityBioGaia’s consistently high gross and EBIT margins indicate a profitable business model with substantial operating economics. This profitability can support investment in products, clinical positioning, and distribution while providing resilience if revenue growth moderates over the next several quarters.

Negative Factors

Free cash flow deteriorationAlthough cash conversion remains healthy in absolute terms, the recent decline in free cash flow weakens the trend in internally generated funds. If sustained, this could reduce the capacity available for product development, distributions, or other strategic uses of cash.

BioGaia AB (0GTN) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: SEK 12.04B
Dividend Yield: 1.37%
Average Volume (3M): 15.08K
Price to Earnings (P/E): 31.5
Beta (1Y): 0.60
Revenue Growth: 13.13%
EPS Growth: 23.94%
Country: UK
Employees: 251
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

BioGaia AB Business Overview & Revenue Model

Company Description

BioGaia AB (publ), a Swedish enterprise founded in 1990 and headquartered in Stockholm, is dedicated to the worldwide development, marketing, and distribution of probiotic products renowned for their scientifically proven health advantages. The compa...

BioGaia AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

GB:0GTN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:SECARE	60Neutral	SEK 3.05B	35.19	1.24%	1.47%	2.73%	36.67%
SE:APOTEA	58Neutral	SEK 9.81B	40.51	―	0.63%	9.35%	-91.93%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SE:ENZY	51Neutral	SEK 534.02M	-15.48	―	―	-2.36%	23.44%
SE:CLBIO	42Neutral	SEK 359.33M	-27.21	―	―	54.37%	52.22%

* General Sector Average

Performance Comparison

GB:0GTN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0GTN	BioGaia AB Class B	120.90	25.40	26.60%
SE:MVIR	Medivir	1.17	0.70	150.43%
SE:SECARE	Swedencare AB	19.00	-16.13	-45.92%
SE:APOTEA	Apotea AB	103.00	17.21	20.06%
SE:ENZY	Enzymatica AB	2.25	0.30	15.38%
SE:CLBIO	Corline Biomedical AB	12.85	-6.60	-33.93%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

BioGaia AB AI Stock Analysis